Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Short Term Effects of Carbidopa-levodopa in Neovascular AMD

Authors not listed

Snyder, Robert W., M.D., Ph.D., P.C. · 2017

Abstract

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to "wet" (neovascular) AMD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2017). Short Term Effects of Carbidopa-levodopa in Neovascular AMD. <em>Snyder, Robert W., M.D., Ph.D., P.C.</em>. https://clinicaltrials.gov/study/NCT03022318
Vancouver
Anonymous. Short Term Effects of Carbidopa-levodopa in Neovascular AMD. Snyder, Robert W., M.D., Ph.D., P.C.. 2017.
BibTeX
@misc{anon2017ShortT, title = {Short Term Effects of Carbidopa-levodopa in Neovascular AMD}, author = {Anonymous}, journal = {Snyder, Robert W., M.D., Ph.D., P.C.}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings